MT-MMP-1 Inhibitors

Chemical inhibitors of MT-MMP 1 operate through a variety of mechanisms to impede the protein's function, which is central to the degradation of extracellular matrix components. Marimastat, for example, is a broad-spectrum MMP inhibitor that binds directly to MT-MMP 1, thereby obstructing its enzymatic action. Similarly, Ilomastat, known as GM6001, employs a hydroxamate-based mechanism to chelate the zinc ion within the active site of MT-MMP 1, which is essential for its catalytic activity. This interaction effectively inhibits the protein's capacity to enact its physiological role. Another inhibitor, Batimastat, acts on MT-MMP 1 by fitting into its catalytic site and preventing the binding of substrate proteins, which is a crucial step for the protein's function. Additionally, Prinomastat and BMS-275291 are selective inhibitors that mimic the structure of collagen to block MT-MMP 1's substrate binding site, thus directly inhibiting the protein's activity. BB-94, which is also referred to as Batimastat, targets the zinc-containing active site of MT-MMP 1, leading to the inhibition of its enzymatic activity. Moreover, SB-3CT and RO-28-2653 are inhibitors that bind to the catalytic domain of MT-MMP 1, preventing access to substrates and thereby reducing the protein's degradation of extracellular matrix components. PD166793 and MMI270 (CGS27023A) occupy the active site of MT-MMP 1, leading to decreased proteolytic function. Lastly, ONO-4817 is an inhibitor that targets the active site of MT-MMP 1, preventing the protein from catalyzing the breakdown of extracellular matrix materials, which is a fundamental aspect of its role within the cellular environment. Each of these inhibitors employs a distinct chemical interaction to inhibit the function of MT-MMP 1, yet all achieve the common outcome of reducing the protein's ability to modify the extracellular matrix through proteolysis.